Vouch, elaborating on this point I'd ask "Do you think that the preclinical and clinical data from Peptron about PT320 will change the FDA's mind on the recommended primary endpoint for the phase III trial for Presendin?"
He probably can't answer that but I'd try
Questions to ask Tom in relation to recent announcement dated 27.09.2021, page-17
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.411M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 7.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.0¢ | 5000 | 1 |
View Market Depth
| Last trade - 16.12pm 17/09/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable